Candriam Luxembourg S.C.A. boosted its position in shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) by 33.3% during the second quarter, Holdings Channel reports. The institutional investor owned 40,000 shares of the company’s stock after buying an additional 10,000 shares during the period. Candriam Luxembourg S.C.A.’s holdings in Aerie Pharmaceuticals were worth $2,102,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Guggenheim Capital LLC boosted its position in shares of Aerie Pharmaceuticals by 4.2% in the fourth quarter. Guggenheim Capital LLC now owns 34,135 shares of the company’s stock worth $1,292,000 after buying an additional 1,384 shares in the last quarter. AQR Capital Management LLC purchased a new position in shares of Aerie Pharmaceuticals during the fourth quarter worth approximately $973,000. Teachers Advisors LLC boosted its position in shares of Aerie Pharmaceuticals by 23.9% in the fourth quarter. Teachers Advisors LLC now owns 47,324 shares of the company’s stock worth $1,791,000 after buying an additional 9,127 shares in the last quarter. Fox Run Management L.L.C. boosted its position in shares of Aerie Pharmaceuticals by 49.3% in the first quarter. Fox Run Management L.L.C. now owns 9,558 shares of the company’s stock worth $433,000 after buying an additional 3,158 shares in the last quarter. Finally, Columbus Circle Investors boosted its position in shares of Aerie Pharmaceuticals by 20.8% in the first quarter. Columbus Circle Investors now owns 282,309 shares of the company’s stock worth $12,803,000 after buying an additional 48,689 shares in the last quarter. 92.98% of the stock is currently owned by hedge funds and other institutional investors.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) opened at 51.45 on Friday. The company’s market capitalization is $1.87 billion. The firm has a 50-day moving average price of $54.69 and a 200-day moving average price of $47.93. Aerie Pharmaceuticals, Inc. has a 52 week low of $17.84 and a 52 week high of $59.50.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its earnings results on Tuesday, August 1st. The company reported ($0.82) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.84) by $0.02. Analysts anticipate that Aerie Pharmaceuticals, Inc. will post ($2.56) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/11/candriam-luxembourg-s-c-a-purchases-10000-shares-of-aerie-pharmaceuticals-inc-nasdaqaeri.html.

A number of research analysts have recently commented on AERI shares. Aegis reaffirmed a “buy” rating and set a $63.00 price target on shares of Aerie Pharmaceuticals in a research report on Thursday, April 13th. HC Wainwright set a $69.00 price objective on Aerie Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, April 15th. Stifel Nicolaus reissued a “buy” rating and set a $65.00 price objective on shares of Aerie Pharmaceuticals in a report on Tuesday, April 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $56.00 price objective on shares of Aerie Pharmaceuticals in a report on Tuesday, April 18th. Finally, Cowen and Company reissued an “outperform” rating and set a $70.00 price objective on shares of Aerie Pharmaceuticals in a report on Tuesday, April 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $66.08.

In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 20,000 shares of the business’s stock in a transaction dated Friday, May 26th. The stock was sold at an average price of $55.95, for a total value of $1,119,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 9.36% of the stock is owned by insiders.

Aerie Pharmaceuticals Company Profile

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Want to see what other hedge funds are holding AERI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aerie Pharmaceuticals, Inc. (NASDAQ:AERI).

Institutional Ownership by Quarter for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.